
Medeia has generated a robust discovery pipeline based on its scientists’ superior understanding and expertise in the molecular mechanisms of neurodegeneration and oncology. We intend to maintain several active R&D programs in the pipeline at all times.Each of the programs shown below consist of a series of potent molecules with potential to next generation back up products.
medeia_therapeutics_pipeline_2010.pdf
Medeia Therapeutics Ltd has been awarded a 0,65 million euro grant from Young Innovative Company (YIC) program financed by Tekes.
Read more...
Medeia Therapeutics receives significant support from Finnish Funding Agency for Technology and Innovation (Tekes)
Read more...
Medeia Therapeutics announces the second financing round led by Inveni Capital
Read more...